Erica Goode

BioTech

How skeptical should you be of an after-the-fact subgroup analysis in a failed clinical trial?

This article was adapted from STAT’s latest report, “Subgroup analysis: how to evaluate post hoc tests for significance in failed clinical trials.” Clinical trials of

Erica Goode October 31, 2023

BioTech

Failed clinical trials don’t always spell doom for a new drug. Here’s why

This article was adapted from STAT’s latest report, “Failed trial, successful drug: how a negative readout can still lead to FDA approval.” When a clinical

Erica Goode August 9, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Erica Goode

How skeptical should you be of an after-the-fact subgroup analysis in a failed clinical trial?

Failed clinical trials don’t always spell doom for a new drug. Here’s why

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe